Publication date: May 28, 2025
Background: Data are limited on 2024-2025 BNT162b2 COVID-19 vaccine effectiveness (VE). Methods: Retrospective cohort study among non-immunocompromised adults from August 22, 2024 (index) to December 31, 2024, among residents of California or Louisiana continuously enrolled in health insurance plans reporting to HealthVerity for >=1 year prior to index. Receipt of 2024-2025 BNT162b2 COVID-19 vaccine was defined using state vaccine registries with health insurance claims, using a time-varying exposure definition. VE against COVID-19-associated hospital admissions was estimated as (1-hazard ratio), using adjusted Cox proportional hazards models with 95% confidence intervals (CI). Results: Overall, 6,900,361 individuals met selection criteria for the study. By the end of follow-up (median 4.4 months), 325,362 (4.7%) had received a BNT162b2 2024-2025 COVID-19 vaccine dose. VE against COVID-19-associated hospital admission was 41% (95% CI 2-64). Discussion: The 2024-2025 formulation of BNT162b2 COVID-19 vaccine provided significant protection, particularly for older adults, in mid-season estimates. This study is registered on clinicaltrials.gov as NCT06923137.
| Concepts | Keywords |
|---|---|
| Diabetes | Bnt162b2 |
| Fdaauthorized | Covid |
| Programmer | Doi |
| Sandwich | Funder |
| Https | |
| Individuals | |
| International | |
| License | |
| Medrxiv | |
| Preprint | |
| Received | |
| Season | |
| Vaccine | |
| Version | |
| Years |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Methionine |
| drug | DRUGBANK | Methylphenidate |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | infection |
| disease | MESH | death |
| disease | MESH | incidental finding |
| disease | MESH | mental illness |
| disease | MESH | influenza |
| disease | MESH | herpes zoster |
| disease | MESH | obesity |
| disease | MESH | diabetes mellitus |
| disease | IDO | history |
| disease | MESH | critical illness |
| disease | MESH | post COVID conditions |
| disease | IDO | country |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | emergency |
| disease | MESH | syndrome |
| disease | MESH | lung diseases |
| disease | MESH | liver diseases |
| disease | MESH | Asthma |
| pathway | KEGG | Asthma |
| disease | MESH | Tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | IDO | blood |
| disease | MESH | Cystic fibrosis |